SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Barclays downgrade of Joby, citing cash burn and doubts about manufacturing capacity, is driving the selloff and comparisons with its upgraded rival Archer. Traders disagree over whether the concerns are justified or the downgrade is a shakeout, with some buying the dip and others moving toward Archer.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivaxs pullback is fueling debate over whether buyout hopes have outrun the near-term case for its ulcerative-colitis drug, obefazimod, despite positive Phase 3 data and a planned FDA filing. Bulls see value in the drugs potential and point to Crohns data as a future catalyst, while skeptics say the lack of a deal could leave the shares waiting on clinical and regulatory milestones; some also cite broader biotech weakness.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase is drawing attention as traders weigh persistent solar-sector pressure from higher borrowing costs and weaker residential demand against its developing IQ SST opportunity for AI data-center power. U.S. production progress and planned demonstrations and customer pilots have fueled rebound and short-squeeze speculation, while skeptics caution that the new business is still unproven and near-term solar headwinds remain.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sareptas depressed, volatile shares are drawing attention amid anticipation of DM1 and FSHD data and questions about ELEVIDYS demand and its regulatory path. Traders also debate whether Novartiss failed DM1 trial is a warning for Sareptas program or a limited read-through given different delivery technology, while frustration over persistent selling contrasts with hopes that upcoming data could rebuild confidence.

KraneShares Trust - KraneShares CSI China Internet ETF

KraneShares CSI China Internet ETF

KWEB is drawing attention around a potential rebound in beaten-down Chinese internet and tech stocks, with traders pointing to bullish options activity, technical support and rotation into China tech. Others remain skeptical, citing the ETFs persistent downtrend, weak market fundamentals and regulatory and geopolitical risks.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

SCHD is drawing attention as investors discuss a rotation between growth stocks and dividend-focused, defensive holdings, with many viewing the ETF as a steadier counterweight to tech volatility. Traders are split between buying dips for long-term income and questioning its recent pullbacks, which some attribute to rising Treasury yields making bonds more competitive.

Verizon Communications, Inc. is a holding company, which engages in the provision of communications, information, and entertainment products and services. It operates through the following business segments: Consumer and Business. The Consumer segment provides consumer-focused wireless and wire line communications services and products. The Business segment offers wireless and wireline communications services and products, including FWA broadband, data, video and conferencing services, corporate networking solutions, security and managed network services, local and long-distance voice services, and network access to deliver various IoT services and products. The company was founded in 1983 and is headquartered in New York, NY.

Verizon Communications Inc

Verizon Communications Inc.

Verizon shares sold off on concerns that SpaceXs planned acquisition of low-band spectrum could help Starlink Mobile compete with established wireless carriers. Traders are split between viewing the threat as a long-term risk to subscribers and pricing and calling the selloff overdone given the time and infrastructure needed to build a competing network, alongside Verizons cash flows and dividend.

Citigroup, Inc. is a holding company, which engages in the provision of financial products and services. It operates through the following segments: Services, Markets, Banking, Wealth, U.S. Personal Banking (USPB), and All Other. The Services segment includes Treasury and Trade Solutions (TTS) which provides an integrated suite of tailored cash management, trade, and working capital solutions to multinational corporations, financial institutions and public sector organizations, and Securities Services, which offers cross-border support for clients, providing on-the-ground local market expertise, post-trade technologies, customized data solutions, and a wide range of securities services solutions that can be tailored to meet client needs. The Markets segment provides corporate, institutional, and public sector clients around the world with a full range of sales and trading services across equities, foreign exchange, rates, spread products, and commodities. The Banking segment offers Investment Banking and Corporate Lending services. The Wealth segment includes Private Bank, Wealth at Work, and Citigold and provides financial services to a range of client segments through banking, lending, mortgages, investment, custody, and trust product offerings. The USPB segment includes Branded Cards and Retail Services, which have proprietary card portfolios and co-branded card portfolios within Branded Cards, and co-brand and private label relationships within Retail Services. The All Other segment consists of activities not assigned to the reportable operating segments, including certain unallocated costs of global functions, other corporate expenses, and net treasury results. The company was founded in 1812 and is headquartered in New York, NY.

Citigroup Inc

Rising yields and expectations ahead of Q3 earnings are weighing on bank stocks, with traders concerned about weaker lending and credit quality even as higher rates could support net interest income. Citi discussion is split between investors calling the pullback a buying opportunity and those anticipating cautious results or guidance.

Cash Cat

A sharp pullback after a speculative rally is driving discussion, with traders debating whether CASHCAT is a pump-and-dump with weak support or a dip worth buying. Bulls cite its Robinhood-chain presence and claimed launchpad-driven buybacks and burns, while those claims and rumors of exchange or executive support remain unverified.

Trulieve Cannabis Corp. engages in the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis Corp 

A DEA administrative law judges pause in the broader cannabis rescheduling proceeding has fueled debate over the delay and weighed on cannabis stocks, including Trulieve. Traders disagree on how exposed TRLV is: some see an industry-wide overreaction because much of Trulieves business is medical, while others remain concerned about uncertainty around Schedule III and related tax relief.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

EnGene Therapeutics Inc. Earnings At $32.50 Mln In Q3

(RTTNews) - enGene Therapeutics Inc. (ENGN) released a profit for third quarter of $32.50 million...

enGene Reports Third Quarter 2026 Financial Results and Provides Business Update

enGene Therapeutics Inc. (Nasdaq: ENGN, enGene or the Company), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the third quarter ended July 31, 2026, and provided clinical and corporate updates. As we move through the second half of 2026, our focus...

enGene to Participate in Upcoming Investor Conferences

enGene Therapeutics Inc. (Nasdaq: ENGN, enGene or the Company), a clinical-stage, non-viral genetic medicines company today announced that management will participate in the following investor conferences: Wells Fargo 21st Annual Healthcare Conference Date: Tuesday, September 8, 2026 Time: 10:15...

enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026

enGene Therapeutics Inc. (Nasdaq: ENGN, enGene or the Company), a clinical-stage, non-viral genetic medicines company, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, August 11, 2026 at 11:00 AM ET featuring Neal Shore, MD, FACS (Carolina Urologic Research...

enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones

enGene Therapeutics Inc. (Nasdaq: ENGN, enGene or the Company), a clinical-stage, non-viral genetic medicines company, today announced changes to its Board of Directors as it plans for potential regulatory milestones and to support commercial readiness for detalimogene voraplasmid (detalimogene) if...

enGene Reports Second Quarter 2026 Financial Results and Provides Business Update

enGene Therapeutics Inc. (Nasdaq: ENGN, enGene or the Company), a clinical-stage, non-viral genetic medicines company today announced its financial results for the second quarter ended April 30, 2026, and provided clinical and corporate updates. Feedback from the urology community on the emerging...

ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm

ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm PR Newswire LOS ANGELES, June 8, 2026 LOS ANGELES, June 8, 2026 /PRNewswire...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN PR Newswire NEW YORK, June 4, 2026 NEW YORK, June 4, 2026 /PRNewswire...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of enGene Therapeutics Inc. (enGene or the Company) (NASDAQ: ENGN) for violations of the securities laws.The investigation focuses on whether the Company issued false...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN PR Newswire NEW YORK, May 21, 2026 NEW YORK, May 21, 2026 /PRNewswire...

enGene Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in developing gene therapies. It is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs. The company was founded by Anthony T. Cheung on April 24, 2023 and is headquartered in Saint-Laurent, Canada.

enGene Therapeutics Inc.

ENGN Stock Soars On Hopeful Data From Bladder Cancer Study

Equity

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$1.73
Prev Close	$1.78
Open	$1.76
Dividend Yield	0.00%
50-Day Moving Average	$1.85
Beta	0.92
Avg. Volume	743,694.85
PE Ratio	-0.83

52-Week High	$12.25
52-Week Low	$1.40
Market Capitalization	$119.29M
EPS (Annual)	-$2.29
Price to Book	0.50
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

ENGN Fundamentals